NOVARTIS-EGF20008



An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
lapatinib
EGF20008
NCT00062686
Neoplasms, Breast
Phase 2
 
The raw dataset is included within the analysis-ready dataset.
June 2014